Level C· Early human research exploring benefitsProspective StudyPubMed

Transplantation of Islet Organoids into Brown Adipose Tissue in a Diabetic Mouse Model.

Sun A., Singh M., Bamrah M., Li W., Aguirre A., Wang P.

Prospective Study on Type 1 Diabetes, Autoimmune Research, published in Methods Mol Biol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Methods Mol Biol (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
39702860
DOI
10.1007/7651_2024_588

Abstract (original English)

Pancreatic islet transplantation is a promising cell replacement therapy for patients with type 1 diabetes (T1D), an autoimmune disease that destroys insulin-producing islet β cells. However, the shortage of donor pancreatic islets significantly limits the widespread use of this strategy as a routine therapy. Pluripotent stem cell-derived insulin-producing islet organoids present a promising alternative β cell source for T1D patients. One critical challenge is the lack of vascularization in islet organoids, making it essential to investigate vascularized transplantation sites to support their survival. Brown adipose tissue (BAT) is well vascularized and secretes active cytokines, facilitating islet organoid survival. Thus, BAT represents a promising transplantation site for islet organoids, making it an ideal location to support cell replacement therapies and improve treatment approaches for T1D. Here, we describe the methods for transplanting human-induced pluripotent stem cell (iPSC)-derived islet organoids into the BAT of a mouse model.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsOrganoidsMiceAdipose Tissue, BrownIslets of Langerhans TransplantationHumansIslets of LangerhansInduced Pluripotent Stem CellsDisease Models, AnimalDiabetes Mellitus, Experimental

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research